

ABN: 27 140 245 263

18 December 2024

ASX Market Announcements Office Australian Securities Exchange 20 Bridge Street Sydney NSW 2000

Release of Restricted Securities - Ecofibre Limited (ASX: EOF)

Ecofibre Limited (Ecofibre or the Company) announces in accordance with Listing Rule 3.10A, that the restriction period for 666,668 Ordinary Fully Paid restricted securities (ASX Code: EOF) held in voluntary escrow will end at the close of trading on 20 December 2024, being 12 months from the issue date.

The Securities purchased by the Directors of Ecofibre as part of the capital raise in 1H24, have been held in voluntary escrow since the issuance on 21 December 2023 and are currently quoted on ASX.

Jonathan Brown Company Secretary Ecofibre Limited

Investor Relations and Media, please contact:

Level 12, 680 George Street, Sydney NSW 2000 Paul Edwards, investor-relations@ecofibre.com

ABN: 27 140 245 263

About Ecofibre

Ecofibre owns a portfolio of high-quality advanced manufacturing and technology businesses in the United States and Australia. We operate three vertically integrated businesses focused on sustainable polymers and natural materials, natural health care, and hemp seed genetics. In addition, we own a majority interest in a life sciences business that is developing treatments for malignant and non-malignant gynaecological conditions.

Ecofibre Advanced Technologies (formerly known as Hemp Black) is an advanced manufacturing business with specialist capabilities in performance yarn extrusion, polymer compounding, and sustainable materials.

Ananda Health is a leading US manufacturer of cannabinoid-based health products for human and pet consumption. Our focus is on providing high-quality, research-backed products in Australia and the USA, targeting conditions including sleep, anxiety, aches and discomfort, and gynaecological conditions. See anandaprofessional.com and anandahemp.com.au.

Ecofibre Genetics owns one of the world's largest collections of hemp seed genetics and is a leading supplier of seed genetics to the hemp fibre and grain industry in the US and Australia.

EOF Bio Inc. is a majority-owned, US-based clinical-stage biotechnology company focused on a new generation of patient- centred cannabinoid-based drugs that improve health outcomes and enhance quality of life, starting with women's health and endometriosis. Spun out of Ecofibre. In July 2023 it is focused on commercialising an expanding estate of issued patents.

Authorisation

This document is authorised to be given to the Australian Securities Exchange (ASX) by the Board of the Company.